Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Sartorius AG    SRT   DE0007165607

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius : launches the new Incucyte SX5® for live-cell analysis...

05/28/2020 | 10:56am EST
DateMay 05, 20
Sartorius AG
Product News
Sartorius launches the new Incucyte SX5® for live-cell analysis, offering new possibilities for live-cell analysis experiments.

Göttingen, May 5th, 2020

  • New, patent pending optical module incorporates long wavelength NIR fluorescence to reduce phototoxicity in long term live-cell experiments
  • Up to five different fluorescence channels allow researchers to explore new applications, such as metabolism, with addition of new live-cell ATP and MMP assays
  • More plex, up to three fluorescence channels and HD phase in a single experiment, enables scientists to extract more data and derive more insight

Sartorius, a leading international supplier for the biopharmaceutical industry, today launched the new Incucyte SX5 Live-Cell Analysis System, the latest in the company's line of live-cell analysis products. The Incucyte SX5 offers new capabilities, including novel optics, a new line of paired reagents, and purpose-built software to enable researchers to draw greater insight from every live cell experiment.

'The Incucyte SX5 contains optics that are designed specifically for long term live-cell experiments and with flexibility in mind. Whether researchers are studying oncology, immuno-oncology, immunology or neuroscience cell models, users will be able to transition seamlessly from one question to the next,' said Kim Wicklund, PhD, Head of Product Management for the Incucyte at Sartorius. 'We are particularly excited to introduce the patent pending optics and analysis including NIR channel in our system, which, in contrast to the blue color channels most other systems use, significantly minimizes phototoxicity in cells.'

With its new optical design, the Incucyte SX5 offers up to five different fluorescence channels, up to three at a time, extending the applications and cell models that can be explored. With the unique fluorescence configuration, plus HD phase optics, more data is generated from every imaging session, enabling unique insights from complex cell models. Researchers can spend weeks preparing a cell culture or other advanced cell model for a single experiment, where different attributes like cell health, proliferation, metabolism, morphology and movement are each visualized with a different channel. Three color channels allow users to not only save time but ask more of their cell models. For instance, co-cultures are easily explored, with two channels used to identify attributes of two cell types, plus a third channel to detect health or function. And because the Incucyte SX5 can address up to six independent microplate experiments in parallel, it streamlines live-cell imaging and analysis in lab settings where multiple individuals are using the instrument concurrently.

Very sensitive cell types can be imaged and analyzed in the Incucyte SX5 for days or months without ever being removed from the incubator. The instrument keeps cell stationary and in a physiologically relevant for the duration of an experiment. All the while, integrated, user-friendly software analyzes the results in real time.

'At Sartorius, our goal is to advance the biomedical field by helping every researcher conduct their dream experiments - the ones that get to the heart of a scientific question - without compromising on experimental setup or conditions,' said Kim. 'The Incucyte product line has already been featured in over 3000 peer reviewed publications. We look forward to seeing what new science is enabled by the Incucyte SX5 as our users explore the new possibilities it offers.'

The Incucyte SX5 will be featured today, May 5th at a free LabTools webinar, 'Live-Cell Analysis in 2020: Advancing Technology to meet Researcher's Needs,' hosted by The Scientist. Speaking at the webinar, Kim Wicklund and Dan Appledorn, PhD, Head of Product Development for Cell Imaging at Sartorius, will discuss the Incucyte and the future of live-cell analysis, and Professor Ted Hinchcliffe will discuss putting live-cell analysis into action in an oncology setting at the Hormel Institute. All are encouraged to attend.

For further information about the Incucyte SX5, please visit www.sartorius.com/Incucyte or contact an expert directly at: askascientist@sartorius.com.

Back to List

Disclaimer

Sartorius AG published this content on 05 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2020 14:55:10 UTC


© Publicnow 2020
All news about SARTORIUS AG
01/15SARTORIUS : Partners With RoosterBio to Advance Cell and Gene Therapy Manufactur..
PU
01/06SARTORIUS : to acquire Novasep's chromatography process equipment...
PU
01/05SARTORIUS STEDIM BIOTECH SA : Bilan SEMESTRIEL S2 -2-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -3-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -2-
DJ
01/04SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
MD
01/04SARTORIUS STEDIM BIOTECH SA : Declaration relative to the number of shares and v..
DJ
2020SARTORIUS : and Evotec Partner With Start-up Curexsys on IPSC-Based...
PU
2020PRESS RELEASE : Evotec and sartorius partner with -2-
DJ
2020SARTORIUS : pays employees a coronavirus bonus
PU
More news
Financials
Sales 2020 2 305 M 2 785 M 2 785 M
Net income 2020 233 M 282 M 282 M
Net Debt 2020 1 759 M 2 125 M 2 125 M
P/E ratio 2020 114x
Yield 2020 0,23%
Capitalization 24 626 M 29 774 M 29 754 M
EV / Sales 2020 11,4x
EV / Sales 2021 9,60x
Nbr of Employees 10 008
Free-Float 46,8%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 246,58 €
Last Close Price 345,00 €
Spread / Highest target 1,74%
Spread / Average Target -28,5%
Spread / Lowest Target -80,1%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chief Executive Officer
Lothar Kappich Chairman-Supervisory Board
Volker Niebel Head-Production, Procurement & Business Operations
Rainer Lehmann Chief Financial Officer
Oscar-Werner Reif Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG0.00%29 774
REVENIO GROUP OYJ-2.88%1 567
ALPHATEC HOLDINGS, INC.-1.86%1 118
CELLAVISION AB (PUBL)1.24%885
VAREX IMAGING CORPORATION10.67%723
OXFORD IMMUNOTEC GLOBAL PLC25.62%570